Supplementary Figure 1 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer

Key Points

• Findings suggest that specific treatments may enhance outcomes in pancreatic cancer patients, improving response rates.
• Correlative analyses highlight relationships between treatment types, such as nivolumab and gemcitabine, and patient responses.
• The analysis supports the use of neoadjuvant therapies in clinical settings, emphasizing their potential benefits.
• Data from supplementary figures illustrate important correlations for optimizing treatment strategies.